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Abstract
Background: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June
2009 on, viral contamination of Genzyme’s production facility resulted in a worldwide shortage of agalsidase beta
leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced dose 0.5 mg/kg/m), or switch to
agalsidase alpha (administered dose 0.2 mg/kg/eow). An assessment report from the European Medicines Agency
(EMA) raised serious concerns about an increase in adverse events at lower dosages of agalsidase beta. We
determined the influence of the shortage on clinical event incidence and the most sensitive biochemical marker
(lysoGb3) in Dutch Fabry patients.
Methods: The incidence of clinical events per person per year was calculated from start of agalsidase beta
treatment until the shortage, and was compared to the incidence of clinical events during the shortage period. In
addition, plasma lysoGb3, eGFR, quality of life (SF-36) and brief pain inventory (BPI) questionnaires were analysed.
Results: All thirty-five Dutch Fabry patients using agalsidase beta (17 males) were included. Mean clinical event
incidence was unchanged: 0.15 events per person per year before versus 0.15 during the shortage (p = 0.68). In
total 28 clinical events occurred in 14 patients during 4.6 treatment years, compared to 7 events in 6 patients
during the 1.3 year shortage period. eGFR and BPI scores were not significantly altered. Two SF-36 subscales were
significantly but minimally reduced in females. In males, lysoGb3 increased with a median of 8.1 nM (range 2.5 -
29.2) after 1 year of shortage (p = 0.001). Increases in lysoGb3 were found in both patients switching to agalsidase
alpha and on a reduced agalsidase beta dose. Antibody status, treatment duration or clinical event incidence
showed no clear correlation to lysoGb3 increases.
Conclusions: No increase in clinical event incidence was found in the adult Dutch Fabry cohort during the
agalsidase beta shortage. Increases in lysoGb3, however, suggest recurrence of disease activity.
Background
Fabry disease (OMIM 301500) is a rare inherited X-
linked lysosomal storage disease. Mutations in the GLA
gene cause a deficiency of the lysosomal enzyme a-
galactosidase A. As a result glycosphingolipids with a
terminal a-galactosyl moiety, predominately globotriao-
sylceramide (Gb3), accumulate in lysosomes [1]. This
accumulation is believed to result in the symptoms and
complications of the disease. During childhood present-
ing symptoms consist of characteristic neuronopathic
pains, gastro-intestinal complaints and hypohidrosis.
Complications usually occur later in life and include
progressive renal insufficiency, stroke, cardiac hypertro-
phy or infarction, and cardiac arrhythmia [2]. The phe-
notype of the disease is very variable, ranging from
severe end-organ damage and early death in classically
affected males to less pronounced disease manifestations
in some male and the majority of female patients.
Enzyme replacement therapy (ERT) is currently the
only approved therapy for Fabry disease and aims at
restoring the defective degradation of accumulated sub-
strates by infusion of recombinant a-galactosidase A. In
2001 the European Medicines Agency (EMA) approved
two recombinant enzyme preparations in Europe: agalsi-
dase alpha (Replagal™, Shire, at a registered dose of 0.2
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at a registered dose of 1.0 mg/kg/eow). In the USA, only
agalsidase beta is licensed. Treatment with both pre-
parations is reported to diminish Gb3 in tissue biopsies,
decrease left ventricular hypertrophy and stabilize renal
function [3-8]. These effects seem most prominent in
patients with less severe organ involvement at start of
therapy [9,10]. Studies on the effect of ERT on the pre-
vention of Fabry related complications are limited. One
phase IV study was conducted showing limited efficacy
of treatment with agalsidase beta showing a modest
decrease in incidence of complications [9]. Such a study
was never performed for agalsidase alpha. Although one
study could not demonstrate differences between agalsi-
dase alpha and agalsidase beta at and equal dose of 0.2
mg/kg/eow [11], the superiority of either one of the pro-
ducts at their registered dose has not been proven so
far.
In June 2009 Genzyme identified a virus (vesivirus
2117) in one of the six bioreactors at their Allston man-
ufacturing facility. Genzyme has reported that this virus
is not known to cause disease in humans. Genzyme
temporarily interrupted its production, which resulted in
a worldwide shortage of agalsidase beta. Assuming a
quick recovery of full production, the EMA advised in
an online press release on 25 June 2009 [12] that: ’
priority should be given to children, adolescent, and
adult male patients. However, adult female patients in
whom the disease is less severe may receive Fabrazyme
at a reduced dose’. This decision was based upon the
supposition that female patients with no clinically signif-
icant end organ damage could more easily tolerate a
lower dose of therapy. In a subsequent online press
release on 23 April 2010 [13] the EMA advised that: ‘
for patients on the reduced dose who demonstrate a
deterioration of the disease, physicians should consider
restarting the original treatment with the full dose of
Fabrazyme or switching to an alternative treatment,
such as Replagal’. Initially, in the Netherlands only less
affected female patients received a reduced dose. How-
ever, from October 2009 persisting shortages forced
dose reductions in all Dutch patients, including males.
In the absence of sufficient agalsidase beta to restore
full dose, Dutch Fabry patients could indicate their pre-
ference to stay at a reduced agalsidase beta dose or
switch to agalsidase alpha.
On 19 October 2010 the EMA released an assessment
r e p o r to nt h es h o r t a g eo fa g a l s i d a s eb e t an o t i n ga n
increase in reporting of adverse events since the start of
the shortage, possibly due to the lowered dose [14].
More specifically, it was stated that: ‘this pattern of
adverse events resembles the natural, but accelerated,
course of Fabry disease’. In addition, the post-marketing
registry on outcomes of treatment with agalsidase beta
(the Fabry Registry, sponsored by Genzyme) showed
that a higher percentage of reports was received of
patients suffering from neuronopathic pains, diarrhoea
and abdominal pain, compared to the period before the
shortage[14]. This suggested increase in adverse events
and complaints is difficult to interpret. It is possible that
indeed a lower dose of agalsidase beta leads to disease
progression or to an accelerated disease course. How-
ever, it is also possible that the anxiety caused by the
shortage and the recommendations by the EMA to treat
patients at full dose of agalsidase beta in case of an
adverse event, led to increased awareness and reporting
of adverse events. Thus, there is a need for objective
data to assess the impact of the agalsidase beta shortage.
We studied the incidence of clinical events per person
p e ry e a rb e f o r ea n dd u r i n gt h es h o r t a g ei nt h ea d u l t
Dutch Fabry cohort. In addition, we analyzed lysoGb3,
eGFR, quality of life (SF-36) and brief pain inventory
(BPI) questionnaires.
Methods
Patients
All adult Dutch Fabry patients treated with agalsidase
beta before the shortage were included in this retrospec-
tive observational study (n = 35). Diagnosis was pre-
viously confirmed by deficient a-galactosidase A activity
(males) and genotyping (males and females). As part of
the standard clinical practice, most patients are routinely
seen at the outpatient clinic every 3 months for record-
ing of complaints and clinical events, physical examina-
tion, and plasma creatinine analysis. In addition, 24-h
urine collections, BPI (Brief Pain Inventory) and SF-36
questionnaires, cardiac ultrasound, electrocardiogram,
hearing tests, and brain imaging are performed on a
yearly basis. All these evaluations were continued during
t h es h o r t a g e .T h eh o s p i t a l ’s Ethical Committee of the
AMC reviewed the protocol and deemed it as being a
non-interventional study, which does not require formal
approval under Dutch law.
Disease progression criteria
Progression of disease was classified as a disease asso-
ciated event according to the following slightly amended
criteria, which were previously described [9,11], or
death. A neurological event was defined as a stroke or
transient ischemic attack as diagnosed by a neurologist.
A renal event was defined as progression of renal dis-
ease to CKD stage 5 (MDRD < 15 ml/min/1.73 m
2,k i d -
ney transplantation, dialysis) or a 33% increase in
plasma creatinine on 2 consecutive time points. A car-
diac event was defined as symptomatic cardiac arrhyth-
mia requiring anti-arrhythmic medication, implantation
of an ICD or pacemaker, hospitalization for heart failure
or cardiac arrhythmia, myocardial infarction, coronary
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inal coronary angioplasty (PTCA). If symptomatic car-
diac arrhythmia coincided with another cardiac event
such as myocardial infarction or hospitalization for car-
diac arrhythmia only one single clinical event was
scored. The clinical event incidence per year per person
was calculated from start of agalsidase beta treatment
until the time of shortage and was compared to the clin-
ical event incidence per year per person during the agal-
sidase beta shortage. Since clinical event incidence may
increase as a result of aging, there is a potential risk of
overestimating the event risk after the shortage when
comparing it to the entire pre-shortage treatment per-
iod. In order to minimize this risk, an equal period of
time directly before the shortage was compared to the
period after the shortage.
Additional clinical evaluations
Decline of glomerular filtration rate (eGFR) was esti-
mated by the abbreviated MDRD [15,16] and was com-
pared for an equal period of time before and during the
shortage. Left ventricular mass was assessed by cardiac
ultrasounds using the Devereux formula indexed for
height [17]. Quality of life (QOL) was assessed using the
SF-36 questionnaire [18]. The SF-36 is a generic ques-
tionnaire with 36 items that measures functional health
and well-being. It comprises eight domains: physical
functioning, role physical, bodily pain, general health,
vitality, social functioning, role emotional, mental health,
and two summary components (consensus on the relia-
bility of the summary components has not yet been
achieved (e.g. [19,20]). Domain and summary compo-
nent scores range from 0-100; higher scores correspond
to better health status or well-being. Minimal important
clinical improvement (MCID) on the SF-36 subscales,
defined as:’ the smallest difference in score in the domain
of interest which patients perceive as beneficial or harm-
ful and which would mandate, in the absence of trouble-
some side effects and excessive costs, a change in the
patient’s health (health care) management’ [21], has
never been determined in Fabry disease. Therefore,
MCID from other chronic illnesses were used for com-
parison [22,23]. Assessment of pain was performed
using the BPI questionnaire. Average BPI and SF-36
scores were calculated for the period of the shortage
and an equal period before the shortage and subse-
quently compared.
Biochemistry
Lysoglobotriaosylceramide (lysoGb3) levels in plasma
were measured with a newly developed method based
on tandem mass spectrometry with isotope labelled
lysoGb3 as internal standard (manuscript in prepara-
tion). Plasma lysoGb3 was investigated in all males and
females who were treated for at least one year with ERT
before start of shortage (since lysoGb3 is known to sta-
bilize thereafter [24]) and with an increased lysoGb3 at
baseline. Lipid concentrations of two plasma samples
before and two during the shortage were available, all
on slightly different time points. Baseline MSSI (Mainz
severity score index[25]) scores were used to assess dif-
ferences between patients experiencing increase in
lysoGb3 or clinical events. Antibody (AB) analysis was
performed by incubating blood of patients with 1 ng
agalsidase beta. The amount of plasma needed to neu-
tralize 50% of the enzymatic activity of 1 ng agalsidase
beta was determined by titration. A sample was deter-
mined not neutralizing when a maximum plasma input
of 15 μl (with a final volume of 200 μl) caused less than
50% neutralization.
Statistical analysis
Statistical analyses were performed using SPSS 16.0
(IBM, Chicago). Continuous data are expressed as med-
ian (range), or mean (SD) when appropriate. Frequen-
cies of clinical events during the shortage between
treatment groups were compared using Fisher exact test.
Differences in clinical event incidence per person per
year and differences in lysoGb3, left ventricular mass,
SF-36 and BPI scores were analysed using paired Wil-
coxon signed rank test. To analyse decline of eGFR
repeated measures were performed using a linear mixed
model. The intercept was included in the random model
as well as the follow-up, thereby optimizing the Akaike
Information criterion. Covariates included follow-up and
the interaction term for follow-up and the shortage per-
iod as a dichotomous variable. Spearman rank tests
were used to assess correlations between lysoGb3 and
clinical response. Two tailed p-values < 0.05 were con-
sidered significant.
Results
Patient characteristics
Thirty-five Fabry patients (17 males) were included in
this study. Median age was 51 years (range: 18-69), with
a median treatment duration until the shortage of 5.4
years (range: 3 months-10.3 yr). The median shortage
duration for all patients was 1.3 (range 0.9-1.5) years.
Patients were divided in three treatment groups: an
immediate switch group, a later switch group and a con-
tinued agalsidase beta group (Figure 1). The immediate
switch group consisted of patients who directly switched
to agalsidase alpha at the start of the agalsidase beta
shortage (n = 2). The later switch group consisted of
patients who first had a dose reduction of agalsidase
beta (from 1.0 mg/kg/eow to 0.5 mg/eow or 0.5 mg/kg/
month) and subsequently switched to agalsidase alpha
( n=1 8 ) .F i n a l l y ,t h econtinued agalsidase beta group
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dose: from 1.0 mg/kg/eow to 0.5 mg/kg/month (n = 15).
The median treatment duration with agalsidase alpha in
the immediate and later switch group was 0.9 year
(range: 0.5-1.4 yr.).
Clinical event incidence during the agalsidase beta
shortage
During the agalsidase beta shortage 7 clinical events
occurred. Five events occurred in patients while their
agalsidase beta dose was reduced, whereas two clinical
events took place after the switch to agalsidase alpha
(see Figure 1). Events included a stroke, an implantation
of a pacemaker because of total atrio-ventricular-block,
1 scheduled implantation of a cardiac defibrillator due
to a non-sustained ventricular tachycardia already pre-
sent before the agalsidase beta shortage, 1 kidney trans-
plantation due to pre-existent chronic kidney failure, 2
hospitalizations because of cardiac arrhythmia, and 1
myocardial infarction. The patients in whom a clinical
event occurred during the shortage were significantly
older: 55.3 vs. 46.7(p = 0.02) compared to those not
having a clinical event, but their median treatment dura-
tion or baseline MSSI did not differ significantly (p =
0.79, respectively p = 0.15). The number of clinical
events which occurred during the agalsidase beta dose
reduction or during the switch to agalsidase alpha did
not differ significantly (p = 0.11).
The median clinical event incidence per person per
year did not differ significantly (p = 0.68), neither for
males and females separately (table 1). When the clinical
event incidence was calculated for an equal period of
time before as during the shortage, no differences in
clinical event incidence were found (male p = 0.25,
females p = 0.14). To compare agalsidase beta 1.0 mg/
k g / e o ww i t ht h ep e r i o do fa g a l s i d a s eb e t ad o s er e d u c -
tion, clinical event incidence was determined until
switch to agalsidase alpha. Again, no significant differ-
ences were found in clinical event incidence (p = 0.77).
eGFR
Two patients were excluded from the analysis: one
patient received a kidney transplant shortly before the
onset of shortage, of the other patient no creatinine
value before the shortage was available. The percentage
of patients using ACE-inhibitors or AT2-antagonist
(64%) during the study was stable and comparable
between groups. Mean MDRD decline per year before
and during the shortage did not differ significantly for
males; before: - 0.81 mL/min/1.73 m
2/year (CI: -5, 3.4),
during: -1.12 (CI:-2.6, 2.0), p = 0.79, or for females;
before: -1.12 (CI: -5.6, 3.3), during: -1.38 (CI:-3.7, 3.20),
p = 0.88.
Left ventricular mass
Analysis of left ventricular mass was restricted due to
limited data. Only 12 patients (3 males) had a cardiac
ultrasound available after one year of the onset of the
shortage. The change in left ventricular mass in these
patients ranged from -13 to + 38 gram/m
2.7 (p = 0.9)
Figure 1 Course of preparations and dosages during agalsidase beta shortage. The numbers in the bars represent the number of patients
in different dosage and preparation groups being the continued agalsidase beta group, the direct and later switch to agalsidase alpha group. The
occurrence of clinical events during agalsidase dose reduction or during switch to agalsidase alpha is outlined on a schematic timeline below
the figure. Abbreviations: CE: clinical events.’
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age or plasma lysoGb3.
Pain assessment using BPI questionnaires
BPI scores before and during the shortage were available
for twenty-nine patients, with a median number of five
questionnaires (range: 3-8). No statistical differences
were found for any of the BPI items before and during
the shortage. Patients for whom BPI was not available
did not report an increase of pain during the shortage.
Quality of Life, SF-36
For thirty patients SF-36 questionnaires were available
before and during the shortage, with a median number
of five questionnaires (range 3-8). Though almost all
scales decreased during the shortage, only statistical sig-
nificant differences were found in females for the
general health perception and vitality subscale (table 2
and Figure 2). Comparing our mean changes to the
minimal clinical important difference determined in
other chronic diseases (general health subscale: 2.4 vital-
ity: 5-7.8) [21-23], the changes were on the borderline
of clinical meaningful differences.
Spontaneous reported complaints during agalsidase beta
shortage
Twenty-three patients reported complaints sponta-
neously at our outpatient clinic. They consisted of:
tiredness (n = 11), gastro-intestinal complaints (n = 3,
pre-existing), increase of angiokeratomas (n = 1), palpi-
tations (n = 3, pre-existing), collapse e.c.i (n = 2, no car-
diac arrhythmia found), angina (n = 5, no proven
ischemia by cardiologist), dyspnoea (n = 2, one new
complaint), and headache (n = 1, pre-existing). Three
Table 1 Clinical event incidence before and during shortage
Before shortage During shortage
CE
n
Mean
follow-up
Mean
CE incidence
Median
CE incidence
Range CE
n
Mean
follow-up
Mean
CE incidence
Median
CE incidence
Range P
Male (n = 17) 20 5.3 0.23 0.17 0-1 3 1.32 0.14 0 0-1.62 0.25
Female (n = 18) 8 3.9 0.07 0 0-0.68 4 1.32 0.16 0 0-0.83 0.40
Total 28 4.6 0.15 0 0-1 7 1.32 0.15 0 0-1.62 0.68
Clinical event (CE) incidence (clinical events per person per year) was compared before and during shortage.
Table 2 SF-36 subscale scores before and during shortage
Before Shortage During Shortage
Male (n = 14) Mean SD Mean SD Mean
difference
CI (95%) Mean difference p
Upper Lower
Physical functioning 60.0 30.1 59.6 26.5 0.4 -9.5 103 0.75
Role physical 43.2 40.4 32.4 35.3 10.7 -11.9 33.2 0.24
Bodily pain 64.3 24.9 60.1 19.2 4.2 -7.7 16.1 0.53
General health 31.2 17.4 36.5 24.8 -5.4 -14 3.2 0.34
Vitality 50.2 17.5 50.0 19.6 0.12 -7.5 7.7 0.7
Social functioning 66.5 30.3 59.8 21.9 6.7 -4 17.4 0.18
Role emotional 57.1 51.4 66.3 39.6 -9.1 -29.5 11.3 0.4
Mental health 74.2 17.4 78.8 13.3 -4.6 -12.1 2.8 0.25
Before Shortage During shortage
Female (n = 16) Mean SD Mean SD Mean
difference
CI (95%) Mean difference p
Upper Lower
Physical functioning 61.5 26.3 58.4 24.8 3.1 -1.9 8.1 0.10
Role physical 36.8 39.8 27.6 40.2 9.2 -3.4 21.9 0.11
Bodily pain 62.3 23.7 61.0 23.5 1.3 -6.8 9.5 0.74
General health 41.4 18.9 37.6 20.9 3.8 0 7.6 0.03
Vitality 42.7 22.1 36.5 23.1 6.1 2.8 9.5 0.003
Social functioning 68.5 18.6 63.1 27.3 5.5 -0.9 11.8 0.11
Role emotional 72.4 34.5 57.3 35.5 15.1 -2.7 32.9 0.15
Mental health 70.7 15.6 66.4 19.6 4.3 -1.1 9.7 0.10
SF-36 scores from females and males separately before and during the shortage. P-values represent SF-36 scores compared before and during the shortage.
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one patient reported pain for the first time. The other
two had no aggravation of previous existing pain.
Plasma lysoGb3
Plasma lyso Gb3 was determined in a subset of 17 patients
(14 males). In males, median lysoGb3 before the shortage
was 22.5 nM (range: 8-63.9) and 32.4 nM (range: 17.1-
93.1) after ± 1 year of shortage. A statistical significant
increase of 8.1 nM (range: 2.5-29.2) lysoGb3 was seen
after approximately 1 year of the shortage (p = 0.001) (see
Figure 3a). For females, median lysoGb3 before the short-
age was 7.1 nM (range: 4.3-9.2) and 8.5 nM (range: 4.9-
8.9) after approximately 1 year of shortage, which was not
statistically different (p = 0.3) (see Figure 3b). The increase
in lysoGb3 in men was significantly larger than in females
(8.1 vs. 0.6 nM, p = 0.003). Values did not return to pre-
treatment values (data not shown). Increase in lysoGb3
was found both in patients who switched to agalsidase
alpha and patients on a reduced agalsidase beta dose (7.4
vs. 6.3 nM p = 0.7). These groups were differed in respect
to lysoGb3 levels in the pre-shortage samples, which
tended to be higher in the reduced agalsidase beta group
(31.5 vs. 16.4 nM, p = 0.07). However, pre-treatment
lysoGb3 values were comparable (p = 0.8).
Relationship between biochemical response and clinical
response
Figure 3c shows that the increase of plasma lysoGb3
levels after 1 year of shortage between males with and
without antibodies to agalsidase beta did not differ sig-
nificantly (8.6 vs. 5.7 nM; p = 0.4). Antibody titers did
not influence the increase of lysoGb3 (data not shown).
There was no correlation between baseline MSSI scores
and increase in lysoGb3 (p = 0.8). Also, treatment dura-
tion or clinical event incidence before or after the short-
age did not correlate to differences in lysoGb3 (p = 0.6,
p = 0.8, p = 0.5).
Discussion
The global enzyme shortage of agalsidase beta and the
subsequent dose reductions caused distress and concern
in both patients and physicians. This was further sup-
ported by an EMA report, describing an increase of
reports of (serious) adverse events suggesting an acceler-
ated course of Fabry disease [14]. We aimed to study
the effects of the shortage by comparing clinical event
incidence in the period before, to clinical event inci-
dence during the shortage in the same patients. In sum-
mary, we did not find an increase in clinical event
incidence during the agalsidase beta shortage or could
establish that a reduced dose of agalsidase beta led to
progression of disease during the shortage in an adult
Fabry cohort. No definite conclusions can be drawn of
the effect on left ventricular mass due to large variation
of the (limited) data. During t h es h o r t a g eq u a l i t yo fl i f e
was significantly reduced in females on the vitality and
general health subscales of the SF-36 questionnaire. The
vitality subscale addresses energy level and tiredness and
the general health perception subscale how patients
experience their health (e.g. expectation of decreasing
health). The SF-36 outcomes reported here are in accor-
dance with earlier reports that demonstrated a decreased
quality of life for male and female Fabry patients [26,27].
Because of the small sample size and wide confidence
intervals, caution should be taken in interpreting these
results, as the SF-36 differences before and during the
shortage were rather small. It is unclear whether these
differences in subscales actually represent a clinical
meaningful detoriation, especially for the individual
patient. This issue, also referred to as ‘minimal clinical
important difference’ (MCID) is determined in many
other chronic diseases. Comparing our mean changes to
the minimal clinical important difference in the litera-
ture [21-23], it can be doubted whether the changes
actually represent a clinical meaningful difference.
The difference in outcome of our study and the EMA
report could be explained by several reasons. As men-
tioned by the EMA, reporting bias due to increased
awareness for adverse events might have overestimated
the number of adverse events reported. The advice of
the EMA to reinstitute the recommended dose in
patients with deterioration of the disease may have sti-
mulated physicians to report adverse events, as this
Figure 2 Mean difference SF-36-scores in females. Error bars
represent 95% confidence intervals. An asterisk represents statistical
significance of p < 0.05.
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Page 6 of 10Figure 3 Individual plasma lysoGb3 levels before and after approximately 1 year of shortage for 3a.m a l e sa n d3b. females. In males a
significant increase of lysoGb3 is seen after 1 year of shortage. 3c. Males with (AB+, solid line) and without antibodies (AB-, dashed line) do not
show a significant difference in lysoGb3 increase. 3d. Percentage increase of lysoGb3 after 1 year of shortage in the continued agalsidase group
vs. later switch group (males only). The continued agalsidase group was dose reduced from 0.5 mg to 0.25 mg/kg/eow. The later switch group
was first dose reduced to 0.5 mg/kg/eow agalsidase beta and subsequently switched tot agalsidase alpha 0.2 mg/kg/eow. In the continued
agalsidase beta group median lysoGb3 value at start of shortage (= 100%) was 31.5 nM and 16.4 nM in the switch group. Abbreviations: Fz:
continued agalsidase beta group (blue line), switch: later switch group (red line).
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their patients. In addition, some of the criteria used to
suggest deterioration during the shortage were of rather
subjective nature (e.g. fatigue, nausea, diarrhoea), but
were nevertheless considered as an adverse event. It is
questionable whether subjective criteria truly represent
clinical detoriation. Finally, the EMA report used the
Fabry registry to assess more objective criteria of clinical
detoriation (occurrence of complications of the disease
e.g. cardiovascular events). The incidence of these events
was too low and the observational period too short to
draw definite conclusions.
Importantly, we could establish an increase in plasma
lysoGb3 in nearly all patients evaluated, following reduc-
tion of the therapeutic enzyme dose. Plasma lysoGb3
elevation is a hallmark of Fabry disease[28] and is asso-
ciated with clinical manifestations[29]. Therefore, this
observation leads to the conclusion that recurrence of
storage material most likely has occurred in these
patients. This is in line with observations made for
lysoGb3 and Gb3 after induction of neutralizing antibo-
dies [24,30,31]. We could not demonstrate a correlation
between clinical event incidence and noted increases of
lysoGb3. The lack of correlation with clinical outcome
could be explained by the fact that enzyme replacement
therapy has at best a modest effect on the course of the
disease. In other words: complications will occur both in
treated and untreated patients, ERT only results in a
slightly different complication rate in patients with
advanced disease [9,10] and at most stabilization of dis-
ease parameters in less severely affected patients [5,8].
Also, on the short term the expected number of clinical
events of this slowly progressive disease would be rather
low. Given the modest treatment effect, it is unlikely
that on the short term a lower dose of enzyme therapy
has a major impact on the incidence of complications in
such a heterogeneous and small cohort. Therefore, on
the short term the biochemical response is probably the
most sensitive way to evaluate the effects of the
shortage.
Interestingly, an increase in lysoGb3 occurred both in
patients with an agalsidase beta reduction to 25% of the
i n i t i a ld o s e( 1m g / k g / e o w )a n dt h o s es w i t c h e dt oa g a l s i -
dase alpha (0.2 mg/kg/eow). We noted that the pre-
shortage lysoGb3 values were higher in the reduced
agalsidase beta group. One might argue that the
expected increase of lysoGb3 in the reduced agalsidase
beta group could be less pronounced than the switch
group, because the pre-shortage values were already at
their near maximum level (i.e. pre-treatment levels).
However, as the pre-shortage samples in the reduced
agalsidase beta g r o u pd i dn o dr e a c hp r e - t r e a t m e n t
values this is unlikely.
All patients with an available lysoGb3 value who
switched to agalsidase alpha were previously dose
reduced on agalsidase beta. Therefore, the increase in
lysoGb3 could be attributed to the reduced agalsidase
beta dose (and not to agalsidase alpha). However, these
patients were approximately treated with agalsidase beta
for six months, and subsequently with agalsidase alpha
f o ra b o u tay e a r .I ti st h e r e f o r em o r el i k e l yt h a tt h e
increase is related to dose rather than preparation. This
supports the earlier observations that not the enzyme
preparation, but the doses are the most important deter-
minants of biochemical response [24]. The importance
of biochemical markers to assess the effects of dose
changes is elegantly shown in Gaucher disease, where
chitotriosidase reflects differences in doses [32] as well
as impact of withdrawal of imiglucerase treatment,
which coincides with clinically relevant deterioration of
disease such as decreases in platelet counts [33-35].
There are several limitations to this study. The period
in which we examined the outcome of the agalsidase
beta shortage was rather short. It is possible that the
incidence of clinical events increases over a longer
observation period. Therefore, studies in larger cohorts,
with a longer follow-up are required. Lastly, it remains
difficult to determine whether the clinical events that
occurred during the shortage-period are caused by the
shortage itself, or by the progressive nature of the dis-
ease despite therapy[9]. The two clinical events that
occurred within a month after the agalsidase beta short-
age (an implantation of a pacemaker and a cardiac defi-
brillator) serve as an example: it is questionable (if not
unlikely) whether these events were caused by a reduced
agalsidase beta dose.
Conclusion
In conclusion, we established no increase in the clinical
event incidence during the shortage of agalsidase beta.
We disagree with the conclusion from the EMA report
of an accelerated course of disease as a result of a lower
dose of Fabrazyme. The impact on the biochemical
response, however, indicates the recurrence of storage
material and supports the supposition that there is a
biochemical dose effect of ERT.
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